Shares of Victrex plc (LON:VCT) have received an average rating of “Hold” from the thirteen research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is GBX 2,488.75 ($32.52).
Several brokerages have issued reports on VCT. UBS Group restated a “buy” rating and issued a GBX 3,600 ($47.04) price target (up from GBX 3,300 ($43.12)) on shares of Victrex in a report on Thursday, October 4th. Peel Hunt restated an “add” rating on shares of Victrex in a report on Wednesday, July 25th. Barclays restated an “underweight” rating and issued a GBX 2,380 ($31.10) price target (up from GBX 2,300 ($30.05)) on shares of Victrex in a report on Tuesday, July 24th. Liberum Capital restated a “buy” rating and issued a GBX 2,825 ($36.91) price target on shares of Victrex in a report on Wednesday, July 25th. Finally, Morgan Stanley increased their price target on Victrex from GBX 1,600 ($20.91) to GBX 2,980 ($38.94) and gave the stock an “equal weight” rating in a report on Monday, July 16th.
LON VCT opened at GBX 2,720 ($35.54) on Friday. Victrex has a 12 month low of GBX 1,826 ($23.86) and a 12 month high of GBX 2,772 ($36.22).
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.